How to Reconstitute TB-500: Step-by-Step Reconstitution Guide

What Is TB-500 and Why Does Reconstitution Matter?

TB-500 is a synthetic analogue of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide that promotes actin polymerization, angiogenesis, and tissue repair. Because peptides are chemically unstable in aqueous solution over time, manufacturers supply TB-500 as lyophilized powder. Reconstitution converts that powder back into an injectable solution.

Done incorrectly, reconstitution can denature the peptide, introduce contamination, or produce an inaccurate concentration that leads to under-dosing or over-dosing. Every step below follows USP General Chapter <1> sterility principles and the FDA's guidance on safe handling of injectable drug products. [1][2]

Why Bacteriostatic Water and Not Sterile Water?

Bacteriostatic water for injection (BWI) contains 0.9% benzyl alcohol, a preservative that inhibits microbial growth between doses. Sterile water for injection (SWFI) contains no preservative and is labeled for single-use only under USP <1> standards. [1] Because TB-500 protocols typically involve multiple draws from one vial over several weeks, BWI is the appropriate diluent. Using SWFI increases contamination risk with every subsequent needle puncture.

Acetic Acid as an Alternative Diluent

Some compounding references suggest 0.6% acetic acid in sterile water for peptides with low aqueous solubility. TB-500 dissolves readily in BWI at room temperature, so acetic acid is generally unnecessary. If a vial does not dissolve fully after gentle swirling, allow it to sit at room temperature for 5 to 10 minutes before re-attempting.

Supplies You Need Before You Start

Gathering every item before you begin prevents mid-procedure contamination. Touching a non-sterile surface while holding an uncapped syringe is one of the most common reconstitution errors in home settings.

Complete Supply Checklist

• TB-500 vial (typically 5 mg lyophilized powder)
• Bacteriostatic water for injection, multi-dose vial
• Two sterile insulin syringes (27 to 31 gauge, 1 mL capacity)
• Alcohol prep pads (70% isopropyl alcohol)
• Clean, flat surface or sterile drape
• Sharps disposal container
• Permanent marker or label for date/concentration

A 1 mL insulin syringe calibrated in 0.01 mL (10-unit) increments gives you the resolution needed to measure doses <0.5 mL accurately. Larger syringes (3 mL, 5 mL) make precise sub-0.1 mL measurements difficult and should be avoided for peptide work. [3]

Step-by-Step TB-500 Reconstitution Protocol

This protocol is written for a standard 5 mg TB-500 vial reconstituted to a final concentration of 2.5 mg/mL using 2 mL of bacteriostatic water.

Step 1, Wash Your Hands and Prepare the Work Surface

Wash hands for a minimum of 20 seconds with soap and water. Lay a clean paper towel or sterile drape on a flat, well-lit surface. Place all supplies within reach. The CDC's hand hygiene guidelines consistently link inadequate handwashing to preventable injection-site infections. [4]

Step 2, Swab Both Vial Stoppers

Wipe the rubber stopper of the TB-500 vial and the stopper of the bacteriostatic water vial with separate alcohol prep pads. Allow each stopper to air-dry for at least 15 seconds. Blowing on the stopper or wiping it twice reintroduces contaminants.

Step 3, Draw the Bacteriostatic Water

Insert a fresh insulin syringe into the bacteriostatic water vial. Invert the vial and draw back the plunger to pull 2 mL (200 units on a U-100 insulin syringe). If your syringe is only 1 mL, you will need two draws; use a fresh syringe for the second draw to preserve needle sharpness and reduce particulate introduction.

Step 4, Inject the Water Slowly Down the Vial Wall

Insert the needle through the center of the TB-500 stopper at a 45-degree angle. Direct the tip toward the glass wall of the vial, not toward the powder cake directly. Depress the plunger slowly so the water runs down the inside wall and pools beneath the powder. Injecting directly onto the lyophilized cake at force can shear peptide bonds and reduce bioactive yield. [5]

Step 5, Swirl, Do Not Shake

Remove the syringe and gently swirl the vial in a slow circular motion for 15 to 20 seconds. You should see the powder dissolve into a clear, colorless solution. Shaking creates air bubbles and mechanical stress that may aggregate the peptide. If any particulate remains after 5 minutes of intermittent gentle swirling, discard the vial and contact your pharmacy or supplier.

Step 6, Inspect the Solution

Hold the vial up to a light source and check for:

• Clarity (should be fully transparent, not cloudy)
• Color (should be colorless to very faintly yellow)
• Particulate matter (none acceptable)

USP <790> Visual Inspection of Injections requires that parenteral solutions be essentially free of visible particulates before administration. [1] Any cloudiness after complete dissolution indicates possible degradation or contamination.

Step 7, Label the Vial

Write the date of reconstitution, the peptide name, and the resulting concentration (e.g., "TB-500 / 2.5 mg per mL / reconstituted 2025-01-28") on a label. Attach it to the vial. Refrigerate immediately at 2 to 8°C.

TB-500 Dosing Calculator and Concentration Math

Getting the concentration math right determines how many units to draw on your insulin syringe for each dose.

Standard Concentration Formula

Concentration (mg/mL) = Mass of peptide (mg) ÷ Volume of diluent added (mL)

| Vial Size | Diluent Added | Concentration | Dose of 5 mg | Dose of 2.5 mg | Dose of 1 mg | |-----------|---------------|---------------|--------------|----------------|--------------| | 5 mg | 1 mL BWI | 5 mg/mL | 1.0 mL (100 units) | 0.50 mL (50 units) | 0.20 mL (20 units) | | 5 mg | 2 mL BWI | 2.5 mg/mL | 2.0 mL (200 units) | 1.00 mL (100 units) | 0.40 mL (40 units) | | 5 mg | 5 mL BWI | 1 mg/mL | 5.0 mL (500 units) | 2.50 mL (250 units) | 1.00 mL (100 units) |

The 2 mL reconstitution volume (yielding 2.5 mg/mL) balances two practical concerns: doses stay small enough to inject subcutaneously without discomfort, yet the concentration is high enough that small syringe errors do not cause large percentage deviations.

How to Read a U-100 Insulin Syringe for Peptide Dosing

U-100 insulin syringes label each unit as 0.01 mL. The arithmetic is direct:

• 10 units = 0.10 mL
• 20 units = 0.20 mL
• 40 units = 0.40 mL
• 100 units = 1.00 mL

At 2.5 mg/mL, a 2 mg dose requires 0.80 mL (80 units). A 5 mg dose requires 2.0 mL, which exceeds one 1 mL syringe and would require two injections or reconstitution with 1 mL instead to keep the volume to 1.0 mL per injection.

Adjusting for Partial Vials

If only 4 mg of powder remains in a partially used vial (a common scenario when a capsule of lyophilized peptide settles unevenly), recalculate the concentration using the actual mass remaining. Assuming 4 mg remains and you add 2 mL BWI, the concentration is 2.0 mg/mL, not 2.5 mg/mL. Drawing 80 units would then deliver 1.6 mg, not 2 mg. Always re-label after adjusting the diluent volume.

Choosing the Right Syringe and Needle for TB-500 Injection

Syringe selection affects both measurement accuracy and injection comfort. For subcutaneous TB-500 administration, a 27 to 31 gauge, 0.5-inch needle is standard. [3]

Subcutaneous vs. Intramuscular Administration

TB-500 is most commonly administered subcutaneously into the abdomen, lateral thigh, or upper arm. Subcutaneous tissue absorbs peptides more slowly than muscle, which may produce a more sustained release profile. Intramuscular administration (typically into the ventrogluteal or vastus lateralis site) is also described in clinical peptide literature and may be appropriate when subcutaneous absorption is inconsistent.

The FDA's guidance document on subcutaneous drug delivery notes that injection volumes above 1.5 mL per SubQ site may increase local irritation and reduce absorption reliability. [6] For doses above 1.5 mL, split the dose across two injection sites or reconstitute at a higher concentration to reduce the per-injection volume.

Needle Gauge and Peptide Viscosity

TB-500 solution at 2.5 mg/mL has viscosity near that of water and flows easily through 31-gauge needles. Higher concentrations (5 mg/mL or above) also flow without difficulty. A 31-gauge needle causes less injection-site bruising than a 27-gauge needle, though individual preference and skin type influence this.

Storage Conditions and Stability After Reconstitution

Peptide stability in aqueous solution depends on temperature, pH, and exposure to light. TB-500 is not unique in this regard: Thymosin Beta-4 chemistry follows the same rules governing other small peptides studied in published stability research.

Refrigerated Storage (2 to 8°C)

Reconstituted TB-500 is stable for up to 28 days when stored at 2 to 8°C in the original vial with the rubber stopper intact. This timeline aligns with the 28-day beyond-use-date (BUD) assigned to multi-dose aqueous preparations containing benzyl alcohol under USP <797> compounding standards. [7]

Freezing Lyophilized Powder (Pre-Reconstitution)

Unreconstituted lyophilized TB-500 powder can be stored frozen at -20°C for 12 to 24 months per manufacturer specifications. Once reconstituted, do not refreeze. Ice crystal formation during freeze-thaw cycles can mechanically disrupt peptide secondary structure. A 2019 stability analysis of small therapeutic peptides in aqueous solution confirmed that freeze-thaw cycling degrades bioactivity more consistently than continuous refrigeration over equivalent time periods. [5]

Light and Temperature Exposure

Keep the reconstituted vial in its original box or wrap it in aluminum foil between uses. Ultraviolet light accelerates oxidation of aromatic amino acid residues. Do not store the vial in a car, near a sunny windowsill, or in any environment where the ambient temperature may exceed 25°C.

Safety Considerations and Red Flags

Recognizing a Contaminated or Degraded Vial

Discard the vial immediately if you observe any of the following:

• Cloudy or milky appearance after full reconstitution
• Visible floating particulates or strand-like material
• Color change (tan, brown, or distinctly yellow)
• Unusual odor when the stopper is removed
• Any vial that was left unrefrigerated for more than 24 hours after reconstitution

The FDA's current good manufacturing practice (cGMP) regulations for injectable drugs require manufacturers to validate that finished parenteral products are free of visible particulates before release. [2] At the point-of-care or home-injection level, visual inspection is the only practical surrogate for that validation.

Injection Site Reactions

Minor redness or a small wheal at the injection site is normal and typically resolves within 30 minutes. Persistent swelling, warmth, or purulent discharge suggests a possible infection and warrants evaluation by a clinician. The risk of injection-site abscess with subcutaneous peptide administration is low when aseptic technique is maintained, but not zero.

Allergy to Benzyl Alcohol

Benzyl alcohol, the preservative in bacteriostatic water, carries a small risk of hypersensitivity. Neonates are at particular risk for gasping syndrome with benzyl alcohol exposure, but in adults, true allergy is rare. If a patient has a documented benzyl alcohol sensitivity, reconstitute with sterile water for injection and treat each draw as a single-use preparation. [1]

Regulatory and Legal Context

TB-500 is not approved by the FDA as a finished drug product for human use as of this writing. It is available from compounding pharmacies as a research compound and, in some jurisdictions, as a compounded preparation under a physician's prescription. The FDA's guidance on compounded drug products under Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding pharmacies that supply peptides like TB-500 to individual patients. [8]

Patients should obtain TB-500 only through a licensed compounding pharmacy with a valid physician's prescription, not through unregulated research-chemical suppliers. Quality, sterility, and concentration accuracy cannot be verified from unregulated sources.

As the Endocrine Society's position statement on compounded bioidentical hormones notes, "compounded preparations lack the FDA-approved manufacturing oversight that ensures consistent potency, purity, and sterility." [9] The same principle applies to compounded peptides.

Common Reconstitution Mistakes and How to Avoid Them

| Mistake | Consequence | Correct Practice | |---------|-------------|-----------------| | Injecting water directly onto powder cake | Potential peptide degradation | Aim water at vial wall | | Shaking the vial | Peptide aggregation, foaming | Swirl gently | | Using sterile water (not bacteriostatic) | Contamination risk on second draw | Use BWI for multi-dose vials | | Storing at room temperature | Accelerated degradation | Refrigerate at 2 to 8°C immediately | | Skipping visual inspection | Risk of injecting a degraded product | Always inspect before each dose | | Reusing the same needle for multiple draws | Particulate introduction, blunted tip | New syringe per draw | | No date label on vial | Risk of using beyond 28-day BUD | Label every reconstituted vial |